Navigation Links
Infinata's BioPharm Clinical™ to Present Session on Improving Investigator Selection at CHI’s Summit for Clinical Operations (SCOPE) on February 6 in Miami, FL
Date:2/1/2013

Norwood, MA (PRWEB) February 01, 2013

On February 6 at 7:45am, BioPharm Clinical™ will present an educational session on improving study feasibility and investigator selection by using patient pool demographic data at CHI’s Summit for Clinical Operations (SCOPE) in Miami, FL. BioPharm Clinical is also co-sponsoring the summit. Topics to be covered in the presentation include the growing importance of international investigators and how to more closely examine U.S. investigators as they become increasingly active in multiple studies that strain their available patients and resources.

Data analytics in BioPharm Clinical and surveys conducted by the company show…

  • The percent of started studies with U.S. sites only has decreased from 54% to 29% since 2000
  • 53% of investigators are located outside of the U.S.
  • Clinical operations professionals surveyed on investigator selection report that their primary concerns are commitment/availability (56%) and patient pool size (41%), far outweighing every other factor offered in the survey
  • 40% of all U.S. investigators who started a new study in the past three years started more than one
  • The average number of active studies per U.S. investigator has increased approximately 50% (from 1.43 to 2.13) since 2000

“These trends demonstrate how critical it is for clinical operations teams to receive the tools and support they need in order to reliably assess study feasibility and to select investigators who will meet enrollment goals,” said session presenter Sean Melville, Business Development Director of BioPharm Clinical. “At SCOPE, we will show how leading global pharmaceutical companies and clinical research organizations (CROs) are leveraging new streams of data including patient pool demographics – such as those available in our +Precision™ database - to make more informed and efficient trial planning decisions.”

In addition to the presentation and co-sponsoring the summit, BioPharm Clinical will partner with Praxis to welcome attendees to a pre-conference reception at Chophouse Miami on February 4 from 6:00-9:00pm. RSVP for the annual networking event and receive a chance to win an iPad Mini.

To view the summit’s full agenda and register to attend, visit http://www.scopesummit.com.

About BioPharm Clinical
BioPharm Clinical is an exclusive support solution for clinical operations professions, providing real-time trial analytics and the most comprehensive database of sites and investigators. Clients benefit from proprietary calculations tailored to their particular trial requirements, detailed milestone timelines and more as they make critical study feasibility assessments and evaluate investigators for their global programs. Learn more at http://www.biopharmclinical.com.

About Infinata, Inc.
Infinata provides personalized technology solutions to turn information into insight. Services include a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson plc. To learn more, visit http://www.infinata.com.

Read the full story at http://www.prweb.com/releases/2013/2/prweb10385646.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Sutro Biopharma Appoints Edward C. Albini as Chief Financial Officer
2. Array BioPharma To Report Financial Results For The Second Quarter Of Fiscal 2013 On February 4, 2013
3. BioPharm Systems to Host Webinar on an Add-On Solution for Oracle Clinical
4. BioPharm Systems to Host Webinar on Self-service Account Management for Oracle Clinical, Remote Data Capture, and Thesaurus Management System
5. Array BioPharma Provides Updates On Clinical Data At The 2012 American Society Of Hematology Meeting
6. TransCelerate BioPharma Inc. Appoints Dalvir Gill as Chief Executive Officer
7. Array BioPharma Announces Exercise And Closing Of Underwriters Over-Allotment Option
8. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
9. PDL BioPharma to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
10. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
11. John A. Orwin Joins Array BioPharma Board Of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the ... the Dow Jones Industrial Average edged 0.27% lower to finish ... 0.17%. Stock-Callers.com has initiated coverage on the following equities: Infinity ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... ). Learn more about these stocks by accessing their free ...
Breaking Biology Technology:
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
Breaking Biology News(10 mins):